No, again wrong....IMHO :-) Progression detected at baseline excludes one from a trial in newly diagnosed GBM trials that exclude recurrent patients/early progressors. In the DCVax-L trial, rule out pseudo-progression might use an additional scan at a second baseline, but if selected into the trial as a pseudo-progressive, they are placed in a separate cohort.
And a couple more scans out to six months??? I thought you already conceded this would be confounded by therapeutic response. It is also not required under RANO and MacDonald criteria.
But hey, I can tell you're trying to pile on with the AF article this morning, so why not throw in the kitchen sink.
News 
Market Data 
Discover 
AI
